Article | May 26, 2017

Top 5 Risks Facing Your Small Biopharma Clients Today

Source: Patheon, part of Thermo Fisher Scientific

By Stephen Lam, SVP, Head of Biologics, Patheon and Jennifer Stone, VP of Quality, Biologics Unit, Patheon

Top 5 Risks Facing Your Small Biopharma Clients Today

Biopharma firms function in a risky development environment with compressed timelines and budget constraints. Companies often overlook critical factors that could delay or suspend efforts down the road. Consultants should help clients understand five key risks in order to avoid costly problems and maximize financial returns during the development process.

In this article, we identify some important risks that consultants should put on the radars of their small biopharma clients. Doing so, along with choosing the right outsourcing partner, will ensure their risks—not their financial returns—are diminished.

Patheon, part of Thermo Fisher Scientific